



Biological Hallmarks of Cancer in Alzheimer's Disease

Kelly N. H. Nudelman^{1,2,3} · Brenna C. McDonald^{1,2,3,4,5} · Debomoy K. Lahiri^{2,5,6} · Andrew J. Saykin^{1,2,3,4,6}

Received: 8 November 2018 / Accepted: 1 April 2019 / Published online: 16 April 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Although Alzheimer's disease (AD) is an international health research priority for our aging population, little therapeutic progress has been made. This lack of progress may be partially attributable to disease heterogeneity. Previous studies have identified an inverse association of cancer and AD, suggesting that cancer history may be one source of AD heterogeneity. These findings are particularly interesting in light of the number of common risk factors and two-hit models hypothesized to commonly drive both diseases. We reviewed the ten hallmark biological alterations of cancer cells to investigate overlap with the AD literature and identified overlap of all ten hallmarks in AD, including (1) potentially common underlying risk factors, such as increased inflammation, deregulated cellular energetics, and genome instability; (2) inversely regulated mechanisms, including cell death and evading growth suppressors; and (3) functions with more complex, pleiotropic mechanisms, some of which may be stage-dependent in AD, such as cell adhesion/contact inhibition and angiogenesis. Additionally, we discuss the recent observation of a biological link between cancer and AD neuropathology. Finally, we address the therapeutic implications of this topic. The significant overlap of functional pathways and molecules between these diseases, some similarly and some oppositely regulated or functioning in each disease, supports the need for more research to elucidate cancer-related AD genetic and functional heterogeneity, with the aims of better understanding AD risk mediators, as well as further exploring the potential for some types of drug repurposing towards AD therapeutic development.

Keywords Alzheimer disease · Cancer · Risk factors · Genetic heterogeneity · Systems biology

Introduction

Alzheimer's disease (AD) imposes a terrible cost on millions of patients as well as their caretakers and is a national health priority. Unfortunately, to date, there has been little progress in developing disease-modifying treatments for this devastating disease. One reason that treatment attempts have been largely unsuccessful may be a result of considering late-onset AD (LOAD) as a “one size fits all” disease. For decades, researchers have been suggesting that, much like cancer, LOAD is actually a heterogeneous compilation of risk and causative factors converging towards

similar symptoms and disease processes. While there are no doubt important commonalities, such as the biological mechanisms leading to buildup of amyloid plaques and tau neurofibrillary tangles, the two major neuropathological characteristics of AD [1], there is also likely to be important differences in subgroups of LOAD patients with differing genetic risk, environmental exposures, and medical histories. While this viewpoint is supported by research, therapeutic research in AD has been largely focused on addressing the two core neuropathologies, with little accommodation for the heterogeneous nature of disease risk, etiology, and progression.

✉ Kelly N. H. Nudelman
kholohan@iu.edu

Andrew J. Saykin
asaykin@iupui.edu

¹ Department of Radiology and
Imaging Sciences, Indiana
University School of Medicine, Indianapolis, IN, USA

² Indiana Alzheimer Disease Center, Indiana University School of
Medicine, Indianapolis, IN, USA

³ Indiana University Center for Neuroimaging, Goodman Hall, Ste.
4100, 355 W. 16th St., Indianapolis, IN 46202, USA

⁴ Indiana University Melvin and Bren Simon Cancer Center, Indiana
University School of Medicine, Indianapolis, IN, USA

⁵ Department of Psychiatry, Indiana University School of Medicine,
Indianapolis, IN, USA

⁶ Department of Medical and Molecular Genetics, Indiana University
School of Medicine, Indianapolis, IN, USA

Cancer history/comorbidity is an aspect of a patient's medical history that may have an important impact on LOAD development and progression. Cancer has been inversely associated with LOAD in numerous epidemiological studies, with cancer shown to reduce the risk of developing LOAD and vice versa [2–7]. These studies accounted for risk factors such as smoking history, sex, and the presence of the apolipoprotein E (*APOE*) ϵ 4 allele, the major known genetic risk factor for LOAD. Additionally, many of these studies have provided evidence that survival bias is not driving this disease association, including a study by Roe et al. [6] showing that cancer and LOAD were inversely associated, while cancer and vascular dementia were not. A recent study of 3,499,378 mostly male US veterans further supports these findings, showing that survivors of numerous cancer types had lower AD risk, though reduced risk was not observed for other age-related conditions, and that chemotherapy was independently associated with lower AD risk [8]. Our previous study showed that cancer history was associated with later onset of LOAD, suggesting that cancer and/or cancer treatment may delay LOAD onset [4]. Importantly, we also found that non-melanoma skin cancer, which is generally benign and only treated with surgical removal, also showed later age of LOAD onset, supporting the idea that beyond cancer treatment effects, the genetic background or environmental exposures predisposing to cancer may be protective towards LOAD.

Although cancer and LOAD have been shown to be inversely associated, there are a surprising number of parallels that can be drawn between these two diseases. Risk for both diseases increases with age and comorbid conditions such as diabetes and metabolic syndrome [9, 10] and appears to be affected by behavioral and environmental factors such as vitamin levels and nutrition, sunlight exposure, smoking, diet and exercise, and heavy metal exposure [11–24]. Genetic factors including microRNAs show evidence of differential expression and activity related to both diseases [25]. Preliminary evidence supports the hypothesis that microRNAs may act as central regulators of both oncogenesis and neurodegeneration [26]. A transcriptomic study using multiple cancer and neurodegenerative disease data sets found significant overlap of pathways both inversely and commonly expressed in cancer and LOAD [27]. Another parallel involves the two-hit model of cancer progression, wherein multiple DNA mutations are necessary for oncogenesis [28]. A similar model has been recently adapted to explain the risk for and progression of AD as well. The two-hit model, when applied to AD, suggests that early-life harmful exposures and/or recessive genetic variants are latent risk factors until later life insults are incurred, at which time additive genetic and epigenetic changes initiate a neuropathological cascade culminating in dementia and death [29–33].

Another interesting parallel between the cancer and LOAD disease processes involves the ten hallmarks of cancer, as updated by Hanahan and Weinberg in 2011 from their original publication in 2000 [34, 35]. All of these hallmarks show some evidence for involvement of key molecules, pathways,

or mechanisms in the risk, onset, or progression of AD (Fig. 1), with some showing evidence of an inverse relationship between cancer and LOAD, while others appear to have parallel or more complicated relationships.











Hallmarks of Cancer in LOAD

Cell Death

The first hallmark of cancer is resistance to cell death. Cell death occurs either by necrosis, in which cell injury results in death by unregulated autolysis, or by apoptosis, programmed cell death [35]. Cancer cells must be able to escape apoptosis, and a common mechanism involves mutations in the pro-apoptotic tumor protein 53 (*TP53*) gene. Somatic inactivating *TP53* mutations have been found in numerous cancer types, while germline mutations in this gene result in Li-Fraumeni syndrome, an autosomal dominant hereditary cancer predisposition syndrome [28, 36–38]. Another example of this mechanism is downregulation of tumor suppressive regulators such as DAPK1; downregulation of this molecule suppresses apoptosis in cancer cells [39].

In contrast, increased cell death is a hallmark of AD; however, there is an ongoing debate regarding the precise mechanisms driving this process [40, 41]. It has been suggested that there are two main types of cell death in AD, apoptosis and neurofibrillary formation. In neurofibrillary formation, cells re-enter the cell cycle, similar to apoptotic initiation. However, there is evidence to suggest that in neurofibrillary formation, cells escape classical apoptosis and instead progress farther through the cell cycle before experiencing neurofibrillary degeneration [42]. There is increasing evidence for involvement of both these types of cell death in AD, supporting the idea of an inverse tendency towards apoptosis in cancer compared with AD. A study of transcriptome data from three types of cancer and neurodegenerative diseases showed that genes in the apoptotic pathway were upregulated in AD [27]. Upregulation of apoptotic proteins has also been observed in the platelets of individuals with mild cognitive impairment (MCI) and AD [43], and studies of genes mutated in familial AD have highlighted the potential involvement of neurodegenerative apoptotic mechanisms [44, 45]. Additionally, it has been shown that amyloid beta induces neuronal death in vitro, and evidence has implicated the pro-apoptotic p53 signaling pathway in this effect [46, 47]. A caspase-independent mechanism involving apoptosis-inducing factor (AIF) has also been identified in AD. Translocation of this protein to the nucleus, which leads to caspase-independent apoptosis, has been observed in AD and was colocalized with neurofibrillary tangles [48]. Upregulation of tumor suppressive regulators such as DAPK1 has been shown in AD brains and has been associated with neuronal apoptotic activity in response to a variety of stimuli, further supporting the potential involvement of

Fig. 1 Hallmarks of cancer in AD. The ten hallmarks of cancer (Hanahan et al., 2011) are listed in the left column (cancer), while in the right column (Alzheimer's disease, AD), known and potential roles of the hallmark pathways or genes/proteins in the hallmark pathways are listed. As shown, all ten hallmarks share functional overlap with known or postulated AD-related biological mechanisms

Cancer		Alzheimer's Disease
Resisting cell death		Increased cell death
Sustaining proliferative signaling		Abnormal proliferative signaling
Evading growth suppressors		Upregulation of growth suppressors
Enabling replicative immortality		Telomere shortening
Inducing angiogenesis		Stage-dependent angiogenic function
Activating invasion and metastasis		Proteins with pleiotropic roles in AD
Genome instability and mutation		Genome instability
Tumor-promoting inflammation		Increased inflammation
Deregulating cellular energetics		Deregulating cellular energetics
Avoiding immune destruction		Increased immune activation

cancer-related apoptotic processes influencing neuronal cell death in AD [49]. Thus, though there is some debate about cellular outcomes (apoptosis vs. neurofibrillary degeneration), it is clear that while apoptotic processes are commonly downregulated or inactivated in cancer, these processes are commonly upregulated or activated in AD. It is possible that a genetic background predisposing towards either upregulation or downregulation of apoptotic processes may contribute towards the inverse association of cancer and AD observed in epidemiological studies.

Proliferative Signaling

The second hallmark of cancer is sustaining proliferative signaling [35]. This can occur through a variety of pathways, including producing more growth factor ligands, signaling to neighboring cells to produce more growth factors, increasing receptor proteins, mutations activating ligand-independent receptor firing, or constitutive activation of downstream growth factor signaling molecules [34, 35]. Somatic mutations for genes within these signaling pathways have been commonly identified in various cancers. For example, activating mutations in the B-Raf proto-oncogene (*BRAF*) are common in melanoma. The mutated protein activates the mitogen-activated protein kinase (MAPK) pathway, inducing proliferation, differentiation, and cell survival [35, 50]. An alternate pathway to MAPK activation common across various cancer types involves activating mutations of small GTPase *RAS* family oncogenes [51, 52]. Interestingly, it has been shown

that while upregulation of oncoproteins involved in tumor growth is a hallmark of cancer, excessive upregulation of these proteins can actually lead to cellular senescence, suggesting that precise regulatory changes are necessary to achieve carcinogenesis [35, 53].

Dysregulated protein kinases important for proliferative signaling have also been identified in AD patients, which is unsurprising given that hyperphosphorylation of neurofibrillary protein tau by protein kinases is one of the hallmarks of AD. The following examples highlight a few results in this complex area and demonstrate the importance of proliferative signaling genes in AD. MAPK/ERK-p has been measured in neurons and glial cells in patients with early-stage tauopathies, and MAPK/ERK-p and phosphorylated protein kinase of 38 kDa (p38) colocalize in neurons and glial cells with phosphorylated tau deposits [54]. Cavallini et al. [55] performed a network analysis that suggested involvement of Ras family GTPases in tau phosphorylation pathways. The small G protein p21ras has been associated with neuritic plaques and tangles in AD [56, 57]. Studies of gene expression in AD have identified the MAPK/ERK pathway as downregulated in AD, as well as brain region-specific altered expression of genes in the PI3K/AKT growth signaling pathway [58–60]. There have been various regional and phosphorylation (activation-state) dependent differences in expression changes observed in kinase signaling pathways for some AD studies, suggesting that altered expression may be associated with an increase in the proportion of activated kinases; this makes sense in the

context of increased phosphorylation of tau associated with advancing disease state [61–63]. The MAPK/ERK pathway is also known to be involved in synaptic plasticity and learning, linking downregulation of genes in this pathway to the cognitive dysfunction observed in AD [58]. These results support the involvement of proliferative signaling genes and pathways in both cancer and AD, and also show the different effects resulting from differential regulation and activity of the same genes in different tissues. Activation/upregulation in somatic tissue is associated with proliferation as one of the hallmarks of cancer, while activation in neurons and glial cells may be one of the initiating steps of tau hyperphosphorylation leading to neurofibrillary tangle formation and cell death, and subsequent downregulation may contribute to decreased synaptic plasticity and cognitive dysfunction in AD.

Growth Suppressors

The third hallmark of cancer is evading growth suppressors. A number of growth suppressor genes, also known as “tumor suppressors,” have been identified as commonly containing inactivating mutations in different cancer types, including the retinoblastoma transcriptional corepressor 1 (*RBI*), *TP53*, and the phosphatase and tensin homolog *PTEN* [35, 64]. Both pRb and p53 proteins regulate cell cycle progression; thus, inactivation of these tumor suppressors permits cell growth and division [65]. *PTEN* negatively regulates the proliferative AKT/PKB signaling pathway [66]. Cells must also be capable of avoiding terminal differentiation, in which cells enter an irreversible post-mitotic state. An oncoprotein commonly overexpressed in cancer, c-Myc, is an example of this process. Upregulation of c-Myc enables it to outcompete transcription factors responsible for initiating differentiation and prevent cells from entering the post-mitotic state [35, 67].

Similarly, evading growth suppressors is a known occurrence in AD. Aberrant neural cell cycle progression is a hallmark of AD and has been linked to neuropathology [68, 69]. Cell cycle studies in AD model organisms suggest that cell cycle re-entry is accompanied by or followed by increased neuropathological processes and apoptosis, while inhibiting cell cycle progression may reduce neurodegeneration [70–72]. Numerous tumor suppressors appear to play important roles in AD neuropathological development [73–77]. For example, p27, an important negative cell cycle regulator, shows enhanced degradation in AD patients compared with controls. Phosphorylated p27, which is marked for degradation, overlaps with neurofibrillary pathology [78, 79]. A number of cell cycle proteins are upregulated in the peripheral lymphocytes of AD patients as well [80–82], suggesting systemic cell cycle dysregulation may be a hallmark of both cancer and AD.

Replicative Immortality

The fourth hallmark of cancer is enabling replicative immortality. All normal cultured cell types have a finite replicative potential, termed the “Hayflick limit.” Once they reach this limit, normal cells stop growing and enter senescence [83]. While cultured cells can circumvent this limit by disabling the pRb and p53 tumor suppressor proteins, the precise mechanisms of cell senescence are still unclear [35]. If cells are able to circumvent the Hayflick limit and continue to divide, they will eventually reach a second limit called the “crisis” state, in which massive genomic instability typically results in cell death [35]. This genomic instability is attributed to critically shortened telomeres, the sequences of DNA that normally protect the ends of each chromosome. To survive this crisis state, the cell must activate telomere maintenance machinery. Typically, this involves upregulation of the telomerase enzyme, which is responsible for elongating telomere sequences in dividing cells and is normally absent or significantly downregulated in somatic cells [35, 84–86]. Activation of telomerase is a critical step in the development of most cancer cells [87].

In contrast, there has recently been accumulating evidence that AD patients have shorter telomeres, and that shorter telomere length is a risk factor for AD [88, 89]. Shorter telomere length could potentially compromise genomic stability, leading to increased amounts of cells undergoing apoptosis in the AD brain. Shorter telomeres would theoretically first impact neurogenesis, as neural stem cells would have shorter telomeres than differentiated neurons due to cell division. There is growing evidence supporting the downregulation of neurogenesis in neurodegenerative diseases, and in particular the importance of neurogenesis in AD [73, 90]. There is also some preliminary evidence from studies of depression supporting the possibility that stress or disease-mediated telomere shortening or reduced telomerase activity could have a deleterious impact on neurogenesis and hippocampal volume [91–93]. The activity of the catalytic subunit of telomerase, TERT, has been shown to have neuroprotective effects in cell and animal models following injury, as well as neuroprotective functions in neurons; due to this, there is increasing interest in telomerase as a therapeutic target in neurological diseases [94].

Angiogenesis

The fifth hallmark of cancer is inducing angiogenesis, or blood vessel formation. All cells in a tissue must reside within 100 μm of a capillary blood vessel to obtain the nutrients and oxygen necessary for survival [34]. In order to grow new cancerous tissue, blood vessel growth is also required [35, 95]. Angiogenesis is carefully regulated in normal tissue, requiring cancer cells to develop the ability to initiate additional

angiogenic signaling and sustain angiogenesis [35, 95]. Based on observations of tumor development, it is postulated that angiogenic induction is an early to middle cancer stage event, which is required for clonal expansion to form a macroscopic tumor [35, 95]. This process is typically achieved by altering the balance of angiogenic inducers (such as vascular endothelial growth factor, VEGF) and inhibitors (such as β -interferon) [35, 96].

Angiogenesis is also a topic of great interest in LOAD research. Cerebral blood flow has been suggested as a biomarker of LOAD, as measurable differences can be detected years before clinical disease presentation via neuroimaging, and can differentiate between cognitively normal individuals, those at risk for LOAD (assessed by family history or brain amyloid), and individuals diagnosed with LOAD [97–99]. There is some evidence that cerebral blood flow may be initially increased, though hypoperfusion is characteristic of later disease stages. Research on cerebral blood flow is complicated by the relationship between cerebral blood flow and brain metabolism, as if metabolism decreases, blood flow will also decrease [100]. Another complication is that it appears that cerebral blood flow may become uncoupled under pathological conditions [101]. Vascular and LOAD pathology commonly co-occur, and the presence of cerebral infarcts has been shown to increase the odds of dementia, specifically impairing memory function [102–104]. Capillary cerebral amyloid angiopathy, the pathological deposition of amyloid beta within cerebral vessels, has been associated with LOAD [105, 106]. All of these findings support a significant role of vascular dysfunction in LOAD. It has been hypothesized that increases in brain regional blood flow observed years prior to LOAD symptoms may represent upregulated angiogenesis as a compensatory mechanism, which then eventually is overtaken by the significant, widespread decrease in blood flow observed in later stage LOAD [97]. A key mechanism driving this stage-dependent vascular functional change may be the different effects of upregulation of hypoxia-inducible factor-1 α (HIF-1 α), known to be upregulated by hypoxia. HIF-1 α upregulates angiogenic factors such as vascular endothelial growth factor (VEGF), which can upregulate angiogenesis, attenuate the pathogenic impact of hypoxia, and potentially delay the onset of LOAD symptoms [107]. However, there is also evidence that HIF-1 α upregulation could exacerbate LOAD neuropathological processes and the activation of the cellular stress response and impairment of autophagy [108]. Thus, while HIF-1 α and angiogenic upregulation may be beneficial in early disease stages to compensate for vascular dysfunction, it may also promote LOAD pathological processes. Furthermore, LOAD neuropathology is associated with reduced capillary expression of VEGF and nitric oxide, two markers of angiogenesis [109], suggesting

that late-stage LOAD brain blood flow decrease may be the result of a vicious neuropathological feedback loop which may also inhibit brain angiogenic repair and maintenance pathways. Thus, angiogenesis regulation may be LOAD stage-dependent and may be an important factor in disease progression and related cognitive dysfunction.

Invasion and Metastasis

The sixth hallmark of cancer is activating invasion and metastasis [35]. While a complete overview of this extremely complex area of study is beyond the scope of this review, we present a few key points for consideration. Advanced-stage cancer cells downregulate cell adhesion molecules promoting contact inhibition, such as E-cadherin and its upstream regulator Reelin, and upregulate adhesion molecules associated with cell migration, such as N-cadherin [110, 111]. Transcription factors associated with migratory processes during embryogenesis are upregulated, possibly in response to stimuli in the tumor microenvironment, resulting in numerous cell structure changes and facilitating the various steps involved in invasion and metastasis [35]. Reelin is a key signaling molecule that has been shown to mediate RAS/PI3K signaling promoting cell motility and tumor metastasis [110].

Cell adhesion and contact inhibition molecules have also been shown to play a role in LOAD. Ibanez et al. [27] found both cell adhesion and extracellular matrix receptor molecules to be downregulated in cancer, but upregulated in LOAD. Cell adhesion was one of the pathways showing significant enrichment of single nucleotide polymorphisms when tested for association with a composite memory score in an LOAD cohort [112], and was also significantly associated with LOAD in two other independent cohorts [113]. Neural cell adhesion molecules are very important for proper synaptic functioning, playing roles in the regulation of synaptic vesicle recycling, stabilization of synaptic membrane interactions, and recruitment of scaffolding proteins and neurotransmitter receptors to the synapse [114]. Interestingly, while Reelin has been shown to mediate cell motility and tumor invasion in cancer, it has also been shown to regulate nervous system development and modulate synaptic plasticity in the adult brain [115]. Reelin also appears to play a more direct role in AD neuropathology, with evidence from mice and humans supporting involvement of Reelin in amyloid plaque formation and tau hyperphosphorylation, and may also be subject to feedback regulation or aggregation by amyloid beta [115–119]. Thus, it appears that in addition to a more straightforward influence on disease risk/progression, cell adhesion pathway genes may also play important pleiotropic roles in LOAD.

Genomic Instability

The seventh hallmark of cancer is genome instability and mutation. This concept was introduced more recently in Hanahan

et al., 2011, as one of two enabling characteristics of cancer. Acquisition of genomic instability generates random mutations, some of which result in the required hallmarks of cancer [35]. It is postulated the genomic instability in cancer cells commonly occurs due to deactivation of genomic maintenance and/or genomic integrity surveillance through such proteins as p53 and BRCA1 [120], as well as telomere erosion accompanied by chromosomal breaks and fusions, resulting in deletion and amplification of numerous segments of DNA [121]. Another piece of evidence for the importance of genomic instability in cancer is the observation of increased aneuploidy, particularly loss of the Y chromosome in men, which has been associated with various cancer types as well as with variants in cancer-related genes [122–125].

Genomic instability is also a topic that has long been of interest in LOAD. Inspired by the knowledge that patients with Down syndrome are more likely to have early-onset AD, linked to an extra copy of the chromosome 21 APP gene, researchers have tried to determine whether neurons in LOAD patients experience copy number gain linked to pathology or cell death. This question is also linked to the theory that neurons re-enter the cell cycle as part of a pathological process leading to cell death [126]. Direct studies of aneuploidy in LOAD have shown mixed results, with some studies supporting copy number gains in select chromosomes measured by fluorescent in situ hybridization (FISH), potentially related to increased neuronal cell death [127–129], while others suggest that aneuploidy may not play an important role in disease initiation/progression [130, 131]. Given the small sample sizes and diverse methods of these studies, as well as the lack of knowledge regarding correlation of aneuploidy with biomarkers and pathology of LOAD, at present, it is not possible to confidently conclude whether autosomal copy number or genome amplification plays an important role in LOAD pathological processes. However, there is increasing literature to suggest that systemic sex chromosome loss may play an important role in aging and LOAD [132–134]. Micronuclei arising from chromosome mis-segregation have been observed at greater frequency in older individuals, those at increased risk for LOAD, and LOAD patients [135], further supporting the importance of genomic instability in LOAD. Finally, shorter telomeres, altered telomere architecture, and telomere shortening over time have been associated with LOAD [88, 89, 136, 137], though there is some inconsistency in this literature as well [138–141], likely partially due to differences in telomere length by cell/tissue type, as well as the very large number of medical, genetic, behavioral, and environmental factors capable of influencing telomere length. Chromosome gain and loss and shorter telomeres may all be important factors in LOAD risk/progression but more research is needed to clarify the roles of these mechanisms.

Inflammation

The eighth hallmark of cancer is tumor-promoting inflammation. This concept is the second enabling characteristic of cancer more recently posited by Hanahan et al. [35]. Tumors have been compared with chronic non-healing wounds, involving chronic inflammation caused by the persistent presence of immune inflammatory cells [142]. These innate immune cells, normally involved in wound healing, are also associated with tissue pathologies including fibrosis, aberrant angiogenesis, and neoplasia [35, 143]. Macrophage subtypes, mast cells, neutrophils, and T and B lymphocytes have all been identified as potentially tumor-promoting [143–147]. To survive, tumors must shift the balance from the subclasses of lymphocytes and innate immune cells attacking the tumor towards the types of immune cells promoting inflammation and tumor growth [35, 147]. It has been posited that inflammation might promote the development of the earliest stages of neoplastic progression, and that a state of chronic systemic inflammation is oncogenic.

The topic of inflammation has long been of interest in AD research [148, 149]. Amyloid plaques and tangles promote a chronic inflammatory feedback loop by inducing the expression and release of pro-inflammatory cytokines by activated microglia, which in turn enhance amyloidogenic processing [150]. “Gliosis,” or the inflammation of microglia and astrocytes, is a hallmark of LOAD; amyloid plaques are typically surrounded by activated microglial cells in early and late phases of disease [151]. While there is evidence that the inflammatory negative feedback loop is likely a toxic contributor to neuropathology, there is also evidence that normal microglial function includes the clearance of amyloid beta, though it is unclear how effective microglia are at this task [151, 152]. A review of select microRNAs in cancer and LOAD literature identified common functional overlap in innate immunity and inflammation and oxidative stress [25]. On an epidemiological level, type 2 diabetes increases the risk of LOAD, and it has been postulated that one of the molecular mechanisms driving this relationship is central and peripheral inflammation [153]. It has been strongly established that systemic inflammation increases with age, and that chronic inflammation is more common in elderly individuals [154]. Inflammation may be one of the common risk factors tying together age-related diseases including cancer and LOAD.

Cellular Energetics

The ninth “emerging” hallmark of cancer is deregulating cellular energetics. Cancer cells have been shown to modify or reprogram cellular metabolism to support proliferation. Cancer cells are known to switch from aerobic oxidative phosphorylation by mitochondria to primarily glycolysis (the Warburg effect [155]) even under aerobic conditions, which better enables hypoxic cells to survive. This switch is

accompanied by upregulated glucose import, which helps to compensate for the difference in glycolytic energy production [35]. In each cell, there are numerous complex, interconnected signaling networks that regulate cellular energetics; in cancer cells, genetic instability promotes the acquisition of genetic mutations, including some that can orchestrate the hallmark functions of cancer and alter cellular metabolism [35]. The hubs of these pleiotropic networks include many genes discussed above, including *RAS* oncogenes, *MYC*, *PTEN*, and *HIF-1 α* , raising the question of whether this is an independent hallmark or a phenomenon tied inextricably to other hallmarks, including proliferation and angiogenesis. One of the regulators of glycogen synthesis, glycogen synthase kinase-3 (GSK3), is regulated by insulin and by the PI3K/Akt signaling pathway, suggesting another point of connection between cancer and diabetes/metabolic syndrome [156]. It should be noted that this emerging hallmark is under debate, however, as other researchers have proposed a “reverse Warburg” hypothesis in which cancer cell metabolism is more complicated [156]. In the reverse Warburg model, cancer cells induce oxidative stress in cancer-associated fibroblasts, causing them to initiate autophagy and undergo glycolysis. Glycolytic byproducts lactate and pyruvate are transferred to epithelial cancer cells undergoing oxidative phosphorylation, essentially allowing cancer cells to feed off the surrounding tissue [157–159]. Notably, stromal cells exhibiting what appears to be a key biomarker of this effect, caveolin-1, show transcriptional similarities to the AD brain transcriptome [157, 158].

Metabolic dysregulation has been studied for decades in LOAD research [160], and LOAD has even been referred to as “type 3 diabetes” [161]. Brain insulin and insulin-like growth factor signaling disturbances and hypometabolism are characteristic of LOAD, including some studies of early disease stages, and hypometabolism has been shown to be correlated with neuropsychological performance deficits [160–168]. This known decrease in glucose metabolism was deemed so significant that [18(F)] fluorodeoxyglucose (FDG) positron emission tomography (PET), an imaging method that can measure glucose metabolism in the brain, has been proposed as a sensitive measure of LOAD progression and a feasible treatment outcome measure [169]. Based on these studies and the hypothesized biology driving metabolic differences in LOAD, a new area of therapeutic interventions is targeting upregulating ketone body metabolism to compensate for dysregulated glucose metabolism in the brain [170–174]. Metabolism was also one of the key functional categories identified as inversely associated in cancer and LOAD by Ibanez et al. (2014). While various metabolic pathways were up- and downregulated in cancer, metabolic pathways were only downregulated in neurodegenerative diseases, including LOAD, and there was a concentration of overlapping metabolic pathways upregulated in cancer and downregulated in LOAD, including oxidative phosphorylation and the Krebs (citric acid)

cycle [27]. Interestingly, one of the key proteins identified in cancer metabolic research, GSK3, has also been identified as playing important roles in LOAD neuropathology, with overexpression linked to increases in tau hyperphosphorylation and tangles as well as differences in amyloid precursor protein processing leading to increased amyloid beta [175]. However, the emerging picture of metabolic differences in LOAD is complex and likely stage- and sex-specific, highlighting this as a topic requiring further investigation.

Immune Function

The tenth “emerging” hallmark of cancer is avoiding immune destruction (immuno-evasion) [35]. Currently, while there is some evidence to support the importance of immune function in suppressing cancer, the importance and efficacy of this function require further research [176, 177]. There is limited evidence supporting the involvement of both the adaptive and innate immune systems in immune surveillance and tumor eradication. Theoretically, cancer cells are selected for those that are weakly immunogenic, not strongly targeted by the immune system. Tumors have also been shown to subvert progenitor immune cells, which then function to suppress normal immune function [35]. Cancer cells could also theoretically disable immune cells by secreting immune-suppressive factors [178]. Though much work remains to be done in this area, immuno-evasion likely plays a role in at least some types of cancer.

While some types of cancer may be characterized by immune resistance, it appears that peripheral as well as central immune function may be a risk factor for LOAD. Peripheral immune cells have been identified in the brain, and it has been suggested that these cells may play a role in exacerbating LOAD processes, though there is currently a debate on this topic [179–181]. The top 20 genes identified by the International Genomics of Alzheimer’s Project (IGAP) showed significant enrichment for the immune response pathway [182]. Furthermore, a recent study identified a SNP in the interleukin-1 receptor accessory protein (IL1RAP) gene as significantly associated with brain amyloid deposition, implicating microglial activation as an important pathway in LOAD [183]. IL1RAP has also been identified as highly upregulated in myeloid leukemia [184], highlighting the potential importance of differential regulation of immune functions in cancer and LOAD. The complement and coagulation cascades and cytokine-cytokine pathways were identified by Ibanez et al. (2014) as downregulated in cancer and upregulated in LOAD, suggesting inverse regulation of immune pathways may play different roles in cancer and LOAD progression. However, more work remains to investigate the roles of the immune system in LOAD risk and progression.

Cancer and LOAD Neuropathology

While some hallmarks of cancer show an inverse association with known function in LOAD, and some appear to have common or complex pleiotropic effects, it is difficult to interpret these findings without a direct link to the two neuropathological hallmarks of LOAD, amyloid and tau pathology. Recent research has started to elucidate this link to LOAD neuropathology. As discussed above, IL1RAP not only was identified as an immune protein that is upregulated in cancer but also has been recently shown to potentially mediate amyloid deposition [183]. The work by Jane Driver and colleagues has identified the protein Pin1 as having key roles in both oncogenesis and LOAD neuropathology [185]. Pin1, which can change the conformation of numerous substrates, has been shown to modulate the amplitude and duration of cellular responses or processes [186]. Pin1 coordinates cell division and is upregulated in many cancer types; however, in LOAD, Pin1 is downregulated or inactivated, and in mouse models, Pin1 absence has been shown to impair tau function and amyloid precursor protein processing, resulting in accumulation of tau tangles and amyloid plaques [185]. Pin1 has neuroprotective functions, as it has been shown to act on both APP and tau to switch their conformations from dysfunction to a functional shape, preventing toxic pathological processes [186]. A study of microRNA roles in cancer and AD by Holohan et al. [25] showed that of the eight reviewed microRNAs, while all had cancer-specific functions, all but one also had functions identified in LOAD studies related to amyloid precursor protein processing or amyloid beta plaque accumulation, or to tau neurofibrillary tangles. Finally, in two large cohorts of deceased older men and women with and without dementia, while there was no difference in neuritic plaque count by cancer history, individuals with cancer history were shown to have lower odds of LOAD proximate to death and significantly fewer neurofibrillary tau tangles at autopsy [187]. While the biological mechanism(s) driving this association remain to be elucidated, there are a number of plausible explanations for the observation of a reduced load of neurofibrillary tau tangles in individuals with cancer history, including cancer survivor selection for improved immune function, survivor behavioral changes leading to healthier brain aging, the influence of chemotherapeutic agents on tau pathology, and/or underlying molecular mechanisms influencing LOAD/cancer risk as well as LOAD neuropathological processes. All of these mechanisms require further investigation to identify potential novel therapeutic directions for cancer and LOAD.

Therapeutic Implications

Cancer drug repurposing has gained significant attention recently as a novel source of potential LOAD therapeutic

agents and was recently reviewed by Heather Snyder and colleagues [7]. The significant overlap of all ten hallmarks of cancer with functions or molecules linked to AD, albeit some with opposite regulation or functions, highlights the importance of this area of study. This is a complicated subject, clearly, with some hallmarks likely to be more suitable for exploration than others. Some molecules may potentially be directly repurposed (i.e., immune checkpoint inhibitors or microtubule stabilizers), while others may need further study (activators vs. inhibitors targeting pathways that appear to be differentially regulated in cancer and AD, such as proliferative and apoptotic pathways). A recent study by Frain et al. [8] showed that




Fig. 2 Cancer and AD model. This model shows the two-hit hypothesis widely accepted as a common mechanism of oncogenesis and more recently proposed to underlie Alzheimer's disease (AD) onset, risk factors including many common to both cancer and AD, and the potential contributions of the hallmarks of cancer to cancer (left) and AD (right). Orange arrows pointing up indicate a posited or observed increase in this hallmark for each disease; blue arrows pointing down indicate a posited or observed decrease in this hallmark for each disease. Black arrows pointing up and down indicate that this hallmark (or molecules involved in this hallmark) show bi-directional, stage-specific, or pleiotropic effects for the disease. It is important to note that many of these hallmarks could be important both before and after the second hit in both diseases, or could be acting at different stages of disease. "Genetics and epigenetics" are listed for both diseases before and after the second hit, as genetic background has been posited to contribute to risk and progression for both diseases (beyond the two key mutations cited in the two-hit model), and also may play a role in differential risk for cancer vs. AD

cancer survivors who had received chemotherapy had a lower risk of AD than those who had not received chemotherapy, further supporting the idea of drug repurposing towards AD therapeutics. Efforts towards cancer drug repurposing in AD are already underway. Based on studies of tau conformational changes related to Pin1 function, it may soon be possible to use an antibody or vaccine to specifically target abnormal protein tau in AD and other tauopathies [186, 188], providing novel treatment options that may be more effective than past efforts aimed at ameliorating amyloid pathology. Another interesting drug repurposing study involves the myeloid cell surface receptor CD33. A SNP in this gene is associated with AD risk [189, 190], while other studies have identified another SNP in linkage disequilibrium that is associated with treatment response in acute myeloid leukemia [191, 192]. Both SNPs were shown to decrease full-length CD33 expression in tissues of interest, which was associated with decreased AD odds ratio, suggesting that antibodies developed for acute myeloid leukemia such as lintuzumab could be effectively repurposed as AD treatments [193]. Drugs blocking immune checkpoints have been shown to mobilize the immune system, resulting in anti-tumor activity [194]. Recent research suggests that these drugs may be repurposed towards AD, as repeated treatment in mouse models has shown reduction of cerebral amyloid beta plaques as well as improved cognitive performance [195]. NSAIDs, which reduce peripheral inflammatory factors, have shown mixed evidence for reduced risk of both cancer and AD [196, 197]. Research on this topic has been complicated by the effects of study duration and design; further research on this type of medication in both diseases seems merited to reach any conclusions. Another interesting target for cancer drug repurposing that has been rather extensively studied is bexarotene, a retinoid X receptor that in cancer functions to suppress proliferation and inhibit inflammatory cell activation [198]. There is some evidence that this drug may also stimulate expression of APOE and increase beta amyloid clearance [199]. The effects of treatment on beta amyloid reduction may be dependent on APOE genotype, and there may be significant cardiovascular risk associated with use [200]; however, this class of drugs represents an interesting new direction leveraging the pleiotropic effects of molecules associated with cancer and AD. While the drugs discussed here are largely involved in immune/inflammatory pathways, given the significant functional overlap of pathways in cancer and AD, it is possible that there are cancer drugs targeting a few of the other hallmarks that may also prove efficacious in AD, or that may suggest novel targets in these pathways. This represents a rich and largely unexplored opportunity for novel AD therapeutic development.

Conclusions

There appears to be significant overlap in disease risk factors and the hallmarks of cancer cells and LOAD, some with opposite, similar, or pleiotropic functions in each disease, as well as a potential direct connection between cancer history and LOAD neuropathology, supporting the idea that cancer history may be an important factor influencing LOAD heterogeneity, risk, and progression (Fig. 2). Some pathways, such as resisting cell death and upregulating growth suppressors, appear to be inversely regulated between these diseases and may help to explain the inverse association of cancer and LOAD observed in epidemiological studies. Other pathways exhibit more complicated pleiotropic roles, including potential effects on LOAD neuropathological pathways. More research is needed to elucidate the molecular mechanisms driving the inverse association of LOAD and specific cancer types, particularly focusing on the mechanism(s) mediating AD neuropathological processes. Additionally, future studies are needed to investigate genetic and molecular factors as biomarkers of risk for both diseases, as well as to continue to explore existing cancer agents in some hallmarks for repurposing towards AD treatments.

Funding Information This work was supported by funding from the National Institutes of Health (R01 AG042437, AG051086, AG029672, AG019771, CA129769, R35 CA197289, P30 AG010133, P30 CA082709, and U01 AG24904).

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

References

1. Perl DP (2010) Neuropathology of Alzheimer's disease. *Mt Sinai J Med* 77(1):32–42
2. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP et al (2012) Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. *BMJ* 344:e1442
3. Musicco M, Adorni F, di Santo S, Prinelli F, Pettenati C, Caltagirone C, Palmer K, Russo A (2013) Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. *Neurology* 81(4):322–328
4. Nudelman KN et al (2014) Association of cancer history with Alzheimer's disease onset and structural brain changes. *Front Physiol* 5:423
5. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC (2005) Alzheimer disease and cancer. *Neurology* 64(5):895–898

6. Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, Williams MM, Kopan R et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. *Neurology* 74(2):106–112
7. Snyder HM, Ahles T, Calderwood S, Carrillo MC, Chen H, Chang CCH, Craft S, de Jager P et al (2017) Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: a convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. *Alzheimers Dement* 13(3):267–273
8. Frain L, Swanson D, Cho K, Gagnon D, Lu KP, Betensky RA, Driver J (2017) Association of cancer and Alzheimer's disease risk in a national cohort of veterans. *Alzheimers Dement* 13:1364–1370
9. Li JQ, Tan L, Wang HF, Tan MS, Tan L, Xu W, Zhao QF, Wang J et al (2016) Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. *J Neurol Neurosurg Psychiatry* 87(5):476–484
10. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA et al (2006) Association of metabolic syndrome with Alzheimer disease: a population-based study. *Neurology* 67(5):843–847
11. Roskies M, Dolev Y, Caglar D, Hier MP, Mlynarek A, Majdan A, Payne RJ (2012) Vitamin D deficiency as a potentially modifiable risk factor for thyroid cancer. *J Otolaryngol Head Neck Surg* 41(3):160–163
12. Malekshah AF, Kimiagar M, Pourshams A, Yazdani J, Kaiedi Majd S, Goglan G, Jaafari E, Semnani S et al (2010) Vitamin deficiency in Golestan Province, northern Iran: a high-risk area for esophageal cancer. *Arch Iran Med* 13(5):391–394
13. Baena Ruiz, R. and P. Salinas Hernandez, Diet and cancer: risk factors and epidemiological evidence. *Maturitas*, 2014. 77(3): p. 202–208.
14. Palmer S (1985) Diet, nutrition, and cancer. *Prog Food Nutr Sci* 9(3–4):283–341
15. Mosconi L, McHugh PF (2015) Let food be thy medicine: diet, nutrition, and biomarkers' risk of Alzheimer's disease. *Curr Nutr Rep* 4(2):126–135
16. Hoel DG, Berwick M, de Gruijl FR, Holick MF (2016) The risks and benefits of sun exposure 2016. *Dermatoendocrinol* 8(1):e1248325
17. Mayeux, R. and Y. Stern, Epidemiology of Alzheimer disease. *Cold Spring Harb Perspect Med*, 2012. 2(8).
18. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y (2015) Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. *PLoS One* 10(3):e0118333
19. Ordonez-Mena JM et al (2016) Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. *BMC Med* 14:62
20. Fair AM, Montgomery K (2009) Energy balance, physical activity, and cancer risk. *Methods Mol Biol* 472:57–88
21. Barnard RJ, Aronson WJ (2005) Preclinical models relevant to diet, exercise, and cancer risk. *Recent Results Cancer Res* 166:47–61
22. Mates JM et al (2010) Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. *Free Radic Biol Med* 49(9):1328–1341
23. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC et al (2008) Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. *J Neurosci* 28(1):3–9
24. Nunez O et al (2017) Association between heavy metal and metalloid levels in topsoil and cancer mortality in Spain. *Environ Sci Pollut Res Int*
25. Holohan KN et al (2012) Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways. *Front Genet* 3:323
26. Satoh J (2012) Molecular network analysis of human microRNA targetome: from cancers to Alzheimer's disease. *BioData Min* 5(1):17
27. Ibanez K et al (2014) Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. *PLoS Genet* 10(2):e1004173
28. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 68(4):820–823
29. Lahiri DK, Maloney B (2010) The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. *Exp Gerontol* 45(4):291–296
30. Lahiri DK et al (2007) How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. *Curr Alzheimer Res* 4(2):219–228
31. Lahiri DK, Maloney B, Zawia NH (2009) The LEARN model: an epigenetic explanation for idiopathic neurobiological diseases. *Mol Psychiatry* 14(11):992–1003
32. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B (2008) Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. *Biogerontology* 9(6):375–379
33. Maloney B, Sambamurti K, Zawia N, K. Lahiri D (2012) Applying epigenetics to Alzheimer's disease via the latent early-life associated regulation (LEARn) model. *Curr Alzheimer Res* 9(5):589–599
34. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. *Cell* 100(1):57–70
35. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144(5):646–674
36. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T (2013) The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. *Nucleic Acids Res* 41(Database issue):D962–D969
37. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. *Hum Mutat* 28(6):622–629
38. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 63(20):6643–6650
39. Tur, M.K., et al., Restoration of DAP kinase tumor suppressor function: a therapeutic strategy to selectively induce apoptosis in cancer cells using immunokinase fusion proteins. *Biomedicines*, 2017. 5(4).
40. LeBlanc AC (2005) The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. *Curr Alzheimer Res* 2(4):389–402
41. Zhu X, Raina A, Perry G, Smith M (2006) Apoptosis in Alzheimer disease: a mathematical improbability. *Curr Alzheimer Res* 3(4):393–396
42. Hamdane M, Delobel P, Sambo AV, Smet C, Bégard S, Violleau A, Landrieu I, Delacourte A et al (2003) Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? *Biochem Pharmacol* 66(8):1619–1625

43. Zhao S, Zhao J, Zhang T, Guo C (2016) Increased apoptosis in the platelets of patients with Alzheimer's disease and amnesic mild cognitive impairment. *Clin Neurol Neurosurg* 143:46–50
44. Czech C, Tremp G, Pradier L (2000) Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. *Prog Neurobiol* 60(4):363–384
45. Kovacs DM et al (1999) Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer's disease mutations in human neuroglioma cells. *J Neurochem* 73(6):2278–2285
46. Akhter R, Sanphui P, Biswas SC (2014) The essential role of p53-up-regulated modulator of apoptosis (Puma) and its regulation by FoxO3a transcription factor in beta-amyloid-induced neuron death. *J Biol Chem* 289(15):10812–10822
47. Akhter R, Sanphui P, Das H, Saha P, Biswas SC (2015) The regulation of p53 up-regulated modulator of apoptosis by JNK/c-Jun pathway in beta-amyloid-induced neuron death. *J Neurochem* 134(6):1091–1103
48. Yu W, Mechawar N, Krantic S, Quirion R (2010) Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease. *Am J Pathol* 176(5):2209–2218
49. You MH, Kim BM, Chen CH, Begley MJ, Cantley LC, Lee TH (2017) Death-associated protein kinase 1 phosphorylates NDRG2 and induces neuronal cell death. *Cell Death Differ* 24(2):238–250
50. Cantwell-Dorris ER, O'Leary JJ, Sheils OM (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. *Mol Cancer Ther* 10(3):385–394
51. Bos JL (1989) ras oncogenes in human cancer: a review. *Cancer Res* 49(17):4682–4689
52. Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. *Expert Opin Ther Targets* 16(1):103–119
53. Nelson DM, McBryan T, Jeyapalan JC, Sedivy JM, Adams PD (2014) A comparison of oncogene-induced senescence and replicative senescence: implications for tumor suppression and aging. *Age (Dordr)* 36(3):9637
54. Ferrer I et al (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. *J Neural Transm (Vienna)* 108(12):1397–1415
55. Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C, Moore R, Calley J et al (2013) An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. *J Biol Chem* 288(32):23331–23347
56. Gartner U et al (1995) Induction of p21ras in Alzheimer pathology. *Neuroreport* 6(10):1441–1444
57. Gartner U, Holzer M, Arendt T (1999) Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. *Neuroscience* 91(1):1–5
58. Hallock P, Thomas MA (2012) Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. *OMICS* 16(1–2):37–49
59. Liu T, Ren D, Zhu X, Yin Z, Jin G, Zhao Z, Robinson D, Li X et al (2013) Transcriptional signaling pathways inversely regulated in Alzheimer's disease and glioblastoma multiform. *Sci Rep* 3:3467
60. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA et al (2008) Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. *Physiol Genomics* 33(2):240–256
61. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. *Curr Alzheimer Res* 2(1):3–18
62. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Bux H, Smith MA (2001) Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. *J Neurochem* 76(2):435–441
63. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J Neurochem* 93(1):105–117
64. Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E et al (2017) Integrative clinical genomics of metastatic cancer. *Nature* 548:297–303
65. Fischer M, Grossmann P, Padi M, DeCaprio JA (2016) Integration of TP53, DREAM, MMB-FOXO1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. *Nucleic Acids Res* 44(13):6070–6086
66. Lim HJ, Crowe P, Yang JL (2015) Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. *J Cancer Res Clin Oncol* 141(4):671–689
67. Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RD, McArthur GA (2008) Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. *Blood* 112(6):2305–2317
68. Keeney JT et al (2012) Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease. *Neurotox Res* 22(3):220–230
69. Bonda DJ, Lee HP, Kudo W, Zhu X, Smith MA, Lee HG (2010) Pathological implications of cell cycle re-entry in Alzheimer disease. *Expert Rev Mol Med* 12:e19
70. Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB (2006) TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. *Curr Biol* 16(3):230–241
71. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM (2013) MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. *J Neurosci* 33(37):14645–14659
72. Lee HG, Casadesus G, Zhu X, Castellani RJ, McShea A, Perry G, Petersen RB, Bajic V et al (2009) Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. *Neurochem Int* 54(2):84–88
73. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. *Proc Natl Acad Sci U S A* 101(7):2173–2178
74. Sonoda Y, Mukai H, Matsuo K, Takahashi M, Ono Y, Maeda K, Akiyama H, Kawamata T (2010) Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. *Neurosci Lett* 471(1):20–24
75. Wilson C, Henry S, Smith MA, Bowser R (2004) The p53 homologue p73 accumulates in the nucleus and localizes to neurites and neurofibrillary tangles in Alzheimer disease brain. *Neuropathol Appl Neurobiol* 30(1):19–29
76. Arendt T, Rödel L, Gärtner U, Holzer M (1996) Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. *Neuroreport* 7(18):3047–3049
77. Lovell MA, Xie C, Xiong S, Markesbery WR (2003) Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. *Brain Res* 983(1–2):84–96
78. Munoz U et al (2008) Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer's dementia patients. *Neurobiol Aging* 29(10):1474–1484

79. Ogawa O, Lee HG, Zhu X, Raina A, Harris PLR, Castellani RJ, Perry G, Smith MA (2003) Increased p27, an essential component of cell cycle control, in Alzheimer's disease. *Aging Cell* 2(2):105–110
80. Kim H, Kwon YA, Ahn IS, Kim S, Kim S, Jo SA, Kim DK (2016) Overexpression of cell cycle proteins of peripheral lymphocytes in patients with Alzheimer's disease. *Psychiatry Investig* 13(1):127–134
81. Song J, Wang S, Tan M, Jia J (2012) G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. *Neurosci Lett* 526(2):144–149
82. Tan M, Wang S, Song J, Jia J (2012) Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. *Neurosci Lett* 516(2):226–231
83. Hayflick, L., Mortality and immortality at the cellular level. A review. *Biochemistry (Mosc)*, 1997. 62(11): p. 1180–1190.
84. Bryan TM, Cech TR (1999) Telomerase and the maintenance of chromosome ends. *Curr Opin Cell Biol* 11(3):318–324
85. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. *EMBO J* 11(5):1921–1929
86. Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. *Proc Natl Acad Sci U S A* 95(25):14723–14728
87. Akincilar SC, Unal B, Tergaonkar V (2016) Reactivation of telomerase in cancer. *Cell Mol Life Sci* 73(8):1659–1670
88. Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Perry G (2016) Meta-analysis of telomere length in Alzheimer's disease. *J Gerontol A Biol Sci Med Sci* 71(8):1069–1073
89. Zhan Y, Song C, Karlsson R, Tillander A, Reynolds CA, Pedersen NL, Hägg S (2015) Telomere length shortening and Alzheimer disease—a Mendelian randomization study. *JAMA Neurol* 72(10):1202–1203
90. Horgusluoglu E, Nudelman K, Nho K, Saykin AJ (2017) Adult neurogenesis and neurodegenerative diseases: a systems biology perspective. *Am J Med Genet B Neuropsychiatr Genet* 174(1):93–112
91. Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H et al (2015) Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. *Transl Psychiatry* 5:e636
92. Wolkowitz OM, Mellon SH, Lindqvist D, Epel ES, Blackburn EH, Lin J, Reus VI, Burke H et al (2015) PBMC telomerase activity, but not leukocyte telomere length, correlates with hippocampal volume in major depression. *Psychiatry Res* 232(1):58–64
93. Yun S, Donovan MH, Ross MN, Richardson DR, Reister R, Fambauch LA, Fischer SJ, Riethmacher D et al (2016) Stress-induced anxiety- and depressive-like phenotype associated with transient reduction in neurogenesis in adult nestin-CreERT2/diphtheria toxin fragment a transgenic mice. *PLoS One* 11(1):e0147256
94. Gonzalez-Giraldo Y et al (2016) Neuroprotective effects of the catalytic subunit of telomerase: a potential therapeutic target in the central nervous system. *Ageing Res Rev* 28:37–45
95. Folkman J (1971) Tumor angiogenesis: therapeutic implications. *N Engl J Med* 285(21):1182–1186
96. Otrrock ZK et al (2007) Understanding the biology of angiogenesis: review of the most important molecular mechanisms. *Blood Cells Mol Dis* 39(2):212–220
97. Wierenga CE, Hays CC, Zlatar ZZ (2014) Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. *J Alzheimers Dis* 42(Suppl 4):S411–S419
98. Tosun D, Schuff N, Jagust W, Weiner MW (2016) Discriminative power of arterial spin labeling magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography changes for amyloid-beta-positive subjects in the Alzheimer's disease continuum. *Neurodegener Dis* 16(1–2):87–94
99. Okonkwo OC, Xu G, Oh JM, Dowling NM, Carlsson CM, Gallagher CL, Birdsill AC, Palotti M et al (2014) Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease. *Cereb Cortex* 24(4):978–988
100. Franceschi M, Alberoni M, Bressi S, Canal N, Comi G, Fazio F, Grassi F, Perani D et al (1995) Correlations between cognitive impairment, middle cerebral artery flow velocity and cortical glucose metabolism in the early phase of Alzheimer's disease. *Dementia* 6(1):32–38
101. Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M, Hatano K, Sasaki T (1998) Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. *Neuroradiology* 40(3):131–137
102. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. *Neurology* 62(7):1148–1155
103. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA (2007) Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. *Ann Neurol* 62(1):59–66
104. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. *Ann Neurol* 66(2):200–208
105. Thal DR, Griffin WST, de Vos RAI, Ghebremedhin E (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. *Acta Neuropathol* 115(6):599–609
106. Jeynes B, Provias J (2006) The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. *Acta Neuropathol* 112(4):417–427
107. Ashok BS, Ajith TA, Sivanesan S (2017) Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease. *Clin Exp Pharmacol Physiol* 44(3):327–334
108. Salminen A, Kauppinen A, Kaarniranta K (2017) Hypoxia/ischemia activate processing of amyloid precursor protein: impact of vascular dysfunction in the pathogenesis of Alzheimer's disease. *J Neurochem* 140(4):536–549
109. Provias J, Jeynes B (2008) Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase. *Curr Neurovasc Res* 5(3):199–205
110. Castellano E, Molina-Arcas M, Krygowska AA, East P, Warne P, Nicol A, Downward J (2016) RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. *Nat Commun* 7:11245
111. Angelucci C, Maulucci G, Lama G, Proietti G, Colabianchi A, Papi M, Maiorana A, de Spirito M et al (2012) Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness. *PLoS One* 7(12):e50804
112. Ramanan VK et al (2012) Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. *Brain Imaging Behav* 6(4):634–648
113. Liu G, Jiang Y, Wang P, Feng R, Jiang N, Chen X, Song H, Chen Z (2012) Cell adhesion molecules contribute to Alzheimer's disease: multiple pathway analyses of two genome-wide association studies. *J Neurochem* 120(1):190–198

114. Leshchynska I, Sytnyk V (2016) Synaptic cell adhesion molecules in Alzheimer's disease. *Neural Plast* 2016:6427537
115. Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, Bender A, Mucke L (2007) Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. *J Neurosci* 27(11):2727–2733
116. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I (2010) Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. *J Neurosci* 30(27):9228–9240
117. Deutsch SI, Rosse RB, Deutsch LH (2006) Faulty regulation of tau phosphorylation by the reelin signal transduction pathway is a potential mechanism of pathogenesis and therapeutic target in Alzheimer's disease. *Eur Neuropsychopharmacol* 16(8):547–551
118. Knuesel I, Nyffeler M, Mormède C, Muhia M, Meyer U, Pietropaolo S, Yee BK, Pryce CR et al (2009) Age-related accumulation of Reelin in amyloid-like deposits. *Neurobiol Aging* 30(5):697–716
119. Cuchillo-Ibanez I et al (2016) The beta-amyloid peptide compromises Reelin signaling in Alzheimer's disease. *Sci Rep* 6:31646
120. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karmali S, Ota A, Wong HY et al (2011) Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. *Proc Natl Acad Sci U S A* 108(43):17773–17778
121. Desmazière C, Soria JC, Freulet-Marrière MA, Mathieu N, Sabatier L (2003) Telomere-driven genomic instability in cancer cells. *Cancer Lett* 194(2):173–182
122. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, de Ståhl TD et al (2014) Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. *Nat Genet* 46(6):624–628
123. Noveski P, Madjunkova S, Sukarova Stefanovska E, Matevska Geshkovska N, Kuzmanovska M, Dimovski A, Plaseska-Karanfilska D (2016) Loss of Y chromosome in peripheral blood of colorectal and prostate Cancer patients. *PLoS One* 11(1):e0146264
124. Wright DJ, Day FR, Kerrison ND, Zink F, Cardona A, Sulem P, Thompson DJ, Sigurjonsdottir S et al (2017) Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility. *Nat Genet* 49(5):674–679
125. Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W et al (2010) Y chromosome loss is a frequent early event in urothelial bladder cancer. *Pathology* 42(4):356–359
126. Yurov YB, Vorsanova SG, Iourov IY (2011) The DNA replication stress hypothesis of Alzheimer's disease. *ScientificWorldJournal* 11:2602–2612
127. Arendt T, Brückner MK, Mosch B, Lösche A (2010) Selective cell death of hyperploid neurons in Alzheimer's disease. *Am J Pathol* 177(1):15–20
128. Arendt T (2012) Cell cycle activation and aneuploid neurons in Alzheimer's disease. *Mol Neurobiol* 46(1):125–135
129. Yang Y, Geldmacher DS, Herrup K (2001) DNA replication precedes neuronal cell death in Alzheimer's disease. *J Neurosci* 21(8):2661–2668
130. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T (2007) Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. *J Neurosci* 27(26):6859–6867
131. van den Bos H, Spierings DC, Taudt AS, Bakker B, Porubský D, Falconer E, Novoa C, Halsema N et al (2016) Single-cell whole genome sequencing reveals no evidence for common aneuploidy in normal and Alzheimer's disease neurons. *Genome Biol* 17(1):116
132. Spremo-Potparevic B, Bajic V, Perry G, Zivkovic L (2015) Alterations of the X chromosome in lymphocytes of Alzheimer's disease patients. *Curr Alzheimer Res* 12(10):990–996
133. Dumanski JP, Lambert JC, Rasi C, Giedraitis V, Davies H, Grenier-Boley B, Lindgren CM, Campion D et al (2016) Mosaic loss of chromosome Y in blood is associated with Alzheimer disease. *Am J Hum Genet* 98(6):1208–1219
134. Spremo-Potparevic B et al (2008) Premature centromere division of the X chromosome in neurons in Alzheimer's disease. *J Neurochem* 106(5):2218–2223
135. Migliore L, Coppede F, Fenech M, Thomas P (2011) Association of micronucleus frequency with neurodegenerative diseases. *Mutagenesis* 26(1):85–92
136. Liu M, Huo YR, Wang J, Wang C, Liu S, Liu S, Wang J, Ji Y (2016) Telomere shortening in Alzheimer's disease patients. *Ann Clin Lab Sci* 46(3):260–265
137. Mathur S, Glogowska A, McAvoy E, Righolt C, Rutherford J, Willing C, Banik U, Ruthirakuhan M et al (2014) Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimer's disease patients. *J Alzheimers Dis* 39(1):35–48
138. Lukens JN, van Deerlin V, Clark CM, Xie SX, Johnson FB (2009) Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. *Alzheimers Dement* 5(6):463–469
139. Thomas P, O.C. NJ, and M. Fenech, Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease. *Mech Ageing Dev*, 2008. 129(4): p. 183–190.
140. Guan JZ, Guan WP, Maeda T, Makino N (2013) Analysis of telomere length and subtelomeric methylation of circulating leukocytes in women with Alzheimer's disease. *Aging Clin Exp Res* 25(1):17–23
141. Roberts RO, Boardman LA, Cha RH, Pankratz VS, Johnson RA, Druliner BR, Christianson TJH, Roberts LR et al (2014) Short and long telomeres increase risk of amnesic mild cognitive impairment. *Mech Ageing Dev* 141–142:64–69
142. Singh K, Singh K (2015) Carcinogenesis and diabetic wound healing: evidences of parallelism. *Curr Diabetes Rev* 11(1):32–45
143. Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R (2017) Tumor promoting role of anti-tumor macrophages in tumor microenvironment. *Cell Immunol* 316:1–10
144. van de Nieuwenhof HP, Hebeda KM, Bulten J, Otte-Holler I, Massuger LFAG, de Hullu JA, van Kempen LCLT (2010) Specific intraepithelial localization of mast cells in differentiated vulvar intraepithelial neoplasia and its possible contribution to vulvar squamous cell carcinoma development. *Histopathology* 57(3):351–362
145. Tang X, Wang S, An C, du P, Yang Y (2017) Preoperative high neutrophil-to-lymphocyte ratio is associated with high-grade bladder cancer. *Anticancer Res* 37(8):4659–4663
146. Lieto E, Galizia G, Auricchio A, Cardella F, Mabilia A, Basile N, del Sorbo G, Castellano P et al (2017) Preoperative neutrophil to lymphocyte ratio and lymphocyte to monocyte ratio are prognostic factors in gastric cancers undergoing surgery. *J Gastrointest Surg* 21:1764–1774
147. DeNardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. *Cancer Metastasis Rev* 29(2):309–316
148. McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. *Alzheimer Dis Assoc Disord* 12(Suppl 2):S1–S6
149. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. *Brain Res Brain Res Rev* 21(2):195–218
150. Serpente M, Bonsi R, Scarpini E, Galimberti D (2014) Innate immune system and inflammation in Alzheimer's disease: from

- pathogenesis to treatment. *Neuroimmunomodulation* 21(2–3):79–87
151. Guillot-Sestier MV, Town T (2013) Innate immunity in Alzheimer's disease: a complex affair. *CNS Neurol Disord Drug Targets* 12(5):593–607
 152. Heneka MT, Golenbock DT, Latz E (2015) Innate immunity in Alzheimer's disease. *Nat Immunol* 16(3):229–236
 153. De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. *Diabetes* 63(7):2262–2272
 154. De la Fuente M, Miquel J (2009) An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflamm-aging. *Curr Pharm Des* 15(26):3003–3026
 155. Warburg O (1925) The metabolism of carcinoma cells. *Journal of Cancer Research* 9(1):148–163
 156. Xu XD, Shao SX, Jiang HP, Cao YW, Wang YH, Yang XC, Wang YL, Wang XS et al (2015) Warburg effect or reverse Warburg effect? A review of cancer metabolism. *Oncol Res Treat* 38(3):117–122
 157. Pavlides S, Tsigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Fortina P et al (2010) Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the “reverse Warburg effect”: a transcriptional informatics analysis with validation. *Cell Cycle* 9(11):2201–2219
 158. Pavlides S, Tsigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG et al (2010) Transcriptional evidence for the “reverse Warburg effect” in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and “neuron-glia metabolic coupling”. *Aging (Albany NY)* 2(4):185–199
 159. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C et al (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. *Cell Cycle* 8(23):3984–4001
 160. de Leon MJ, George AE, Ferris SH, Rosenbloom S, Christman DR, Gentes CI, Reisberg B, Kricheff II et al (1983) Regional correlation of PET and CT in senile dementia of the Alzheimer type. *AJNR Am J Neuroradiol* 4(3):553–556
 161. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. *J Diabetes Sci Technol* 2(6):1101–1113
 162. Steen E, Terry BM, J. Rivera E, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? *J Alzheimers Dis* 7(1):63–80
 163. de Leon MJ, Ferris SH, George AE, Christman DR, Fowler JS, Gentes C, Reisberg B, Gee B et al (1983) Positron emission tomographic studies of aging and Alzheimer disease. *AJNR Am J Neuroradiol* 4(3):568–571
 164. Cutler NR (1986) Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome. *Prog Neuro-Psychopharmacol Biol Psychiatry* 10(3–5):309–321
 165. McGeer PL, McGeer EG, Hisaki K, Wong K (1986) Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease. *Prog Neuro-Psychopharmacol Biol Psychiatry* 10(3–5):501–518
 166. Tamminga CA, Foster NL, Fedio P, Bird ED, Chase TN (1987) Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. *Neurology* 37(1):161–165
 167. Mann UM, Mohr E, Gearing M, Chase TN (1992) Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. *J Neurol Neurosurg Psychiatry* 55(10):956–959
 168. Silverman DH et al (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. *JAMA* 286(17):2120–2127
 169. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. *Am J Psychiatry* 159(5):738–745
 170. Ding F, Yao J, Rettberg JR, Chen S, Brinton RD (2013) Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. *PLoS One* 8(11):e79977
 171. Henderson ST (2008) Ketone bodies as a therapeutic for Alzheimer's disease. *Neurotherapeutics* 5(3):470–480
 172. Hertz L, Chen Y, Waagepetersen HS (2015) Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, beta-amyloid toxicity, and astrocyte function. *J Neurochem* 134(1):7–20
 173. VanItallie TB (2015) Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. *Metabolism* 64(3 Suppl 1):S51–S57
 174. Cunnane SC et al (2016) Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer's disease. *Front Mol Neurosci* 9:53
 175. Small SA, Duff K (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. *Neuron* 60(4):534–542
 176. Osborn JL, Greer SF (2015) Metastatic melanoma cells evade immune detection by silencing STAT1. *Int J Mol Sci* 16(2):4343–4361
 177. Pandey JP (2014) Immunoglobulin GM genes, cytomegalovirus immunoevasion, and the risk of glioma, neuroblastoma, and breast cancer. *Front Oncol* 4:236
 178. Kawasaki BT, Farrar WL (2008) Cancer stem cells, CD200 and immunoevasion. *Trends Immunol* 29(10):464–468
 179. McManus RM, Mills KH, Lynch MA (2015) T cells-protective or pathogenic in Alzheimer's disease? *J NeuroImmune Pharmacol* 10(4):547–560
 180. McManus RM, Heneka MT (2017) Role of neuroinflammation in neurodegeneration: new insights. *Alzheimers Res Ther* 9(1):14
 181. Mietelska-Porowska A, Wojda U (2017) T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer's disease: potential pools of new biomarkers. *J Immunol Res* 2017:4626540
 182. International Genomics of Alzheimer's Disease, C (2015) Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimers Dement* 11(6):658–671
 183. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD et al (2015) GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. *Brain* 138(Pt 10):3076–3088
 184. Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, Juliusson G, Richter J et al (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. *Blood* 121(18):3709–3713
 185. Driver JA, Zhou XZ, Lu KP (2015) Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease. *Biochim Biophys Acta* 1850(10):2069–2076
 186. Driver JA, Zhou XZ, Lu KP (2014) Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease. *Discov Med* 17(92):93–99
 187. Yarchoan M, James BD, Shah RC, Arvanitakis Z, Wilson RS, Schneider J, Bennett DA, Arnold SE (2017) Association of cancer history with Alzheimer's disease dementia and neuropathology. *J Alzheimers Dis* 56(2):699–706

188. Lu KP, Kondo A, Albayram O, Herbert MK, Liu H, Zhou XZ (2016) Potential of the antibody against cis-phosphorylated tau in the early diagnosis, treatment, and prevention of Alzheimer disease and brain injury. *JAMA Neurol* 73(11):1356–1362
189. Lambert JC et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 45(12):1452–1458
190. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, Gallins PJ, Buxbaum JD et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* 43(5):436–441
191. Lamba JK, Pounds S, Cao X, Downing JR, Campana D, Ribeiro RC, Pui CH, Rubnitz JE (2009) Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. *Leukemia* 23(2):402–404
192. Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B et al (2013) Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. *Clin Cancer Res* 19(6):1620–1627
193. Malik M, Chiles J, Xi HS, Medway C, Simpson J, Potluri S, Howard D, Liang Y et al (2015) Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. *Hum Mol Genet* 24(12):3557–3570
194. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW et al (2012) PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. *Cancer Res* 72(20):5209–5218
195. Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, Kertser A, David E et al (2016) PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. *Nat Med* 22(2):135–137
196. Sauer CM, Myran DT, Costentin CE, Zwisler G, Safder T, Papatheodorou S, Mucci LA (2018) Effect of long term aspirin use on the incidence of prostate cancer: a systematic review and meta-analysis. *Crit Rev Oncol Hematol* 132:66–75
197. Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, Tang SW, Yu JT (2015) Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. *J Alzheimers Dis* 44(2):385–396
198. Liby KT, Sporn MB (2016) Rexinoids for prevention and treatment of cancer: opportunities and challenges. *Curr Top Med Chem*
199. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, Casali BT, Restivo JL et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. *Science* 335(6075):1503–1506
200. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M et al (2016) Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. *Alzheimers Res Ther* 8:4

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.